At LionsHub Capital, we are committed to identifying and nurturing groundbreaking technologies that have the potential to create a profound impact on both environment and society. Today, we are thrilled to announce that Ibticare, a pioneering startup in the field of antimicrobial solutions, has been selected to join our prestigious accelerator program.
Overcoming Antimicrobial Resistance
Ibticare’s Innovative Solution
Ibticare has emerged as a unique solution in this battle against AMR/MDR, armed with a revolutionary Physical Vapor Deposition (PVD) technology that embeds advanced antimicrobial nanoparticles onto various surfaces. This groundbreaking approach has the potential to revolutionize infection control in healthcare facilities, public spaces, and various industries.
At LionsHub Capital, we recognize the huge potential of Ibticare’s innovative solutions and their alignment with our mission to drive positive change through strategic investments. By selecting Ibticare for our accelerator program, we are providing them with a tailored investment plan, access to premium network of industry leaders, and invaluable guidance to navigate the scaling phase and meet the highest industrial requirements.
This partnership incubation is a testament to our belief in the power of collaboration and the importance of fostering an ecosystem that supports and accelerates the development of transformative technologies.
Ibticare’s groundbreaking technology embodies the kind of moonshot thinking that business leader advocates – bold ideas that can transform entire industries.
Together, we will work tirelessly to amplify Ibticare’s impact, ensuring that their solutions reach the forefront of the global fight against bacterial infection.
